Gujarat Themis Biosyn
Gujarat Themis Biosyn Limited is one of India’s research-based API fermentation companies having plants at Vapi, Hyderabad with group turnover of over $ 40 million. It has EDMFs, available and WHO approved plants. & it is a India’s first company to start commercial production of Anti-tuberculosis drug Rifampicin produced by fermentation process. Now chairman of company is Dr. Dinesh Patel,( Ph.D.) It is being actively managed by Themis Medicare Ltd. (JV company of Gedeon Richter Ltd, Hungary) since 2007.
GTBL was incorporated in 1981 jointly by GIIC and chemosyn (P) Ltd. GIBL commenced production in Aug. 1985 by producing antibiotic erythromycin, and erythromycin salts and formulations. GTBL was a sick company which was forced to discontinue production because of accumulated losses. Then - Kopran alongwith Cadila Healthcare Ltd., Lyka Labs Ltd., Themis Chemicals Ltd. and Anant & Co., formed Pharmaceutical Business Group (India) Ltd. in 1990. PBG acquired Gujarat Themis Biosyn Ltd (GTBL) as a sick company from BIFR in collaboration with Yuhan Corporation, South Korea and became India’s first producer of Rifampicin.Yuhan has provided technology for Rifampicin from fermentation and invested in equity also.
The company has world–wide exports to satisfied customers, having customised facility for all products. The company exports its products to Europe and the United States. Group Companies are Pharmaceutical Business Group (India) Ltd., Themis Medicare Limited, Yuhan Corporation, South Korea – (JV).
FOLLOW US!
Call Now